OptimizeRx Co. (NASDAQ:OPRX) saw a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 734,200 shares, a decrease of 13.2% from the January 15th total of 845,500 shares. Based on an average daily volume of 107,800 shares, the days-to-cover ratio is currently 6.8 days. Approximately 6.4% of the company’s stock are short sold.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Citigroup Inc. raised its position in OptimizeRx by 304.2% in the 4th quarter. Citigroup Inc. now owns 2,765 shares of the company’s stock valued at $28,000 after buying an additional 2,081 shares during the last quarter. Barclays PLC grew its stake in OptimizeRx by 34.7% in the 3rd quarter. Barclays PLC now owns 10,403 shares of the company’s stock valued at $151,000 after purchasing an additional 2,678 shares during the period. California State Teachers Retirement System grew its stake in OptimizeRx by 16.5% in the 3rd quarter. California State Teachers Retirement System now owns 21,500 shares of the company’s stock valued at $311,000 after purchasing an additional 3,049 shares during the period. UBS Group AG grew its stake in OptimizeRx by 34.9% in the 4th quarter. UBS Group AG now owns 17,000 shares of the company’s stock valued at $175,000 after purchasing an additional 4,397 shares during the period. Finally, Squarepoint Ops LLC grew its stake in OptimizeRx by 25.0% in the 3rd quarter. Squarepoint Ops LLC now owns 27,000 shares of the company’s stock valued at $391,000 after purchasing an additional 5,400 shares during the period. 61.22% of the stock is owned by institutional investors and hedge funds.

NASDAQ OPRX traded down $0.13 on Friday, reaching $10.58. The company had a trading volume of 12,403 shares, compared to its average volume of 68,458. The stock has a market capitalization of $149.96 million, a P/E ratio of -117.56 and a beta of 0.31. The company’s fifty day moving average is $10.46 and its 200 day moving average is $12.43. OptimizeRx has a 52-week low of $8.63 and a 52-week high of $17.24. The company has a quick ratio of 7.00, a current ratio of 7.00 and a debt-to-equity ratio of 0.01.

A number of brokerages have recently weighed in on OPRX. Zacks Investment Research lowered OptimizeRx from a “hold” rating to a “sell” rating in a research report on Tuesday, November 5th. B. Riley lowered their price target on OptimizeRx from $21.00 to $20.00 and set a “buy” rating for the company in a research report on Monday, December 30th. TheStreet lowered OptimizeRx from a “c” rating to a “d+” rating in a research report on Wednesday, November 20th. ValuEngine raised OptimizeRx from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 4th. Finally, William Blair started coverage on OptimizeRx in a research report on Friday, January 3rd. They issued an “outperform” rating for the company. One analyst has rated the stock with a sell rating, two have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $18.00.

OptimizeRx Company Profile

OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care.

Read More: Guidelines for Successful Channel Trading

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.